Must not have known allergic reaction against any of the components of the study treatment
Patient has previously taken ruxolitinib or is allergic to components of the study drug
Patient with documented hypersensitivity to any of the components of the therapy program
Patients with documented hypersensitivity to any components of the study program
Patient with documented hypersensitivity to any of the components of the chemotherapy program
Patient with documented hypersensitivity to any of the components of the chemotherapy program
Patient with documented hypersensitivity to any of the components of the chemotherapy program
Known prior severe allergic/hypersensitivity to the chemotherapy or any of the components of the study treatment
Known allergic reaction to neratinib, pertuzumab, trastuzumab, paclitaxel, or any of their components
Patient is allergic to components of the study drug; for arms A and B only, patient has perviously taken ibrutinib
Any known allergic reaction to vaccine components
